ensitrelvir

Also known as 1-(2,4,5-trifluorobenzyl)-3-[(1-methyl-1H-1,2,4-triazol-3-yl)methyl]-(6E)-6-[(6-chloro-2-methyl-2H-indazol-5-yl)imino]-1,3,5-triazinane-2,4-dione, S-217622

thumb|right|75px|Xocova in a Japanese blister pack

Key facts

Drug.image: Ensitrelvir.svg
Drug.image_class: skin-invert-image
Drug.tradename: Xocova
Drug.routes_of_administration: By mouth
Drug.ATC_prefix: J05
Drug.ATC_suffix: AE11
Drug.legal_status: JP: Rx-only
Drug.elimination_half life: 42–48 hours
Drug.CAS_number: 2647530-73-0
Drug.CAS_number2: 2757470-18-9
Drug.PubChem: 162533924
Drug.DrugBank: DB18834
Drug.ChemSpiderID

~5 min read

Article

7 sections

Contents

Medical uses
History
Society and culture
Legal status
Names
Research
References

thumb|right|75px|Xocova in a Japanese blister pack

Ensitrelvir, sold under the brand name Xocova is an antiviral medication used as a treatment for COVID-19. It was developed by Shionogi in partnership with Hokkaido University and acts as an orally active 3C-like protease inhibitor. It is taken by mouth.